PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 65.56

Change

-0.68 (-1.02)%

Market Cap

N/A

Volume

4.84K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.07 (+0.05%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

-0.08 (-0.12%)

USD 2.70B
FXH First Trust Health Care AlphaD..

-0.53 (-0.50%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

-0.83 (-0.98%)

USD 0.18B
IDNA iShares Genomics Immunology an..

-0.47 (-2.12%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.67 (-2.16%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.12 (+0.12%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.32 (-1.12%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-1.27 (-2.07%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-2.73%)

USD 6.67M

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.46% 33% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.46% 33% F 41% F
Trailing 12 Months  
Capital Gain 1.51% 67% D+ 49% F
Dividend Return 0.01% 6% D- N/A F
Total Return 1.52% 62% D 35% F
Trailing 5 Years  
Capital Gain 56.02% 43% F 46% F
Dividend Return 0.18% 11% F N/A F
Total Return 56.20% 43% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain 4.32% 57% F 48% F
Dividend Return 4.34% 48% F 41% F
Total Return 0.02% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 19.67% 48% F 55% F
Risk Adjusted Return 22.07% 52% F 37% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.